- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/50 - Facteur de croissance des fibroblastes [FGF]
Détention brevets de la classe C07K 14/50
Brevets de cette classe: 731
Historique des publications depuis 10 ans
|
67
|
60
|
59
|
47
|
47
|
46
|
54
|
55
|
60
|
28
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| NGM Biopharmaceuticals, Inc. | 178 |
41 |
| Amgen Inc. | 4122 |
24 |
| Novartis AG | 10707 |
21 |
| Florida State University Research Foundation, Inc. | 773 |
20 |
| New York University | 1749 |
20 |
| The Salk Institute for Biological Studies | 445 |
18 |
| Bristol-myers Squibb Company | 4840 |
15 |
| 89bio, Inc. | 23 |
15 |
| The Regents of the University of California | 20153 |
14 |
| Yuhan Corporation | 234 |
14 |
| Novo Nordisk A/S | 2272 |
12 |
| Ambrx, Inc. | 182 |
11 |
| Sanofi | 4101 |
11 |
| Wisconsin Alumni Research Foundation | 3885 |
10 |
| Eli Lilly and Company | 3898 |
10 |
| Sunshine Lake Pharma Co., Ltd. | 599 |
9 |
| Ubiprotein, Corp. | 12 |
8 |
| Board of Trustees of the University of Arkansas | 823 |
7 |
| Trefoil Therapeutics, Inc. | 12 |
7 |
| Ampsource Biopharma Shanghai Inc. | 47 |
7 |
| Autres propriétaires | 437 |